Dafna Capital Management LLC Portfolio Holdings

Dafna Capital Management LLC

  • $389 Million
  • Q3 2024

Dafna Capital Management LLC has filed its 13F form on November 14, 2024 for Q3 2024 where it was disclosed a total value porftolio of $389 Million distributed in 84 stocks.

Among their holdings, we can observe that their the top five positions include companies like: Spdr Ser Tr Spdr S&P Biotech E with a value of $39.7M, Stereotaxis, Inc. with a value of $27.9M, Revolution Medicines, Inc. with a value of $23.5M, Cytokinetics Inc with a value of $21M, and Merus N.V. with a value of $20.6M.

Examining the 13F form we can see an decrease of $1.04M in the current position value, from $390M to 389M.

Dafna Capital Management LLC is based out at Los Angeles, CA

Below you can find more details about Dafna Capital Management LLC portfolio as well as his latest detailed transactions.

Portfolio value $389 Million
Healthcare: $334 Million
ETFs: $54.6 Million

Stock Holdings Table

Stock Market Cap. Holding Value (Reported) # of Shares. Last Trade Trade History
$131M
$1.14 Million 0.29% of portfolio
329,579
Q2 2024 Reduced 1.35%
$27.5B
$1.01 Million 0.26% of portfolio
8,500
Q3 2024 New
$36M
$864,000 0.22% of portfolio
600,000
Q1 2024 New
$122M
$809,000 0.21% of portfolio
447,202
Q3 2024 Reduced 3.25%
$307M
$780,000 0.2% of portfolio
108,200
Q3 2024 Reduced 6.88%
$155M
$642,000 0.17% of portfolio
204,081
Q2 2024 New
$87.9M
$543,000 0.14% of portfolio
125,000
Q3 2024 New
$9.09B
$399,000 0.1% of portfolio
3,000
Q3 2018 Reduced 40.0%
$326M
$350,000 0.09% of portfolio
37,664
Q3 2024 Reduced 10.0%
$108M
$324,000 0.08% of portfolio
341,064
Q1 2024 Reduced 2.85%
$151M
$215,000 0.06% of portfolio
116,882
Q1 2023 Reduced 80.59%
$23.2M
$238,000 0.06% of portfolio
313,717
Q3 2021 Added 23.65%
$160M
$212,000 0.05% of portfolio
38,000
Q3 2024 Added 35.71%
$40.7M
$167,000 0.04% of portfolio
125,000
Q3 2022 New
$67M
$159,000 0.04% of portfolio
192,678
Q4 2022 New
Acelyrin Inc
-
$0 0.0% of portfolio
-
Q3 2024 Reduced 13.08%
Ascendis Pharma A/S
-
$0 0.0% of portfolio
-
Q2 2023 New
Biohaven LTD
-
$0 0.0% of portfolio
-
Q3 2024 Reduced 14.45%
Verastem Inc
-
$0 0.0% of portfolio
-
Q3 2024 New
Alto Neuroscience Inc
-
$0 0.0% of portfolio
-
Q3 2024 Reduced 77.68%
Biomx Inc
-
$0 0.0% of portfolio
-
Q3 2024 New
-
$0 0.0% of portfolio
-
Q3 2024 Reduced 7.36%
Aprea Therapeutics Inc
-
$0 0.0% of portfolio
-
Q1 2024 New
Grail Inc
-
$0 0.0% of portfolio
-
Q3 2024 New
Lexeo Therapeutics Inc
-
$0 0.0% of portfolio
-
Q3 2024 New
Mediwound LTD
-
$0 0.0% of portfolio
-
Q3 2024 Reduced 48.2%
$0
$0 0.0% of portfolio
148,294
Q3 2024 Reduced 38.0%
Mineralys Therapeutics Inc
-
$0 0.0% of portfolio
-
Q3 2024 Added 23.11%
Neurogene Inc
-
$0 0.0% of portfolio
-
Q3 2024 Reduced 29.32%
Nyxoah S A
-
$0 0.0% of portfolio
-
Q2 2024 New
Perspective Therapeutics Inc
-
$0 0.0% of portfolio
-
Q3 2024 Reduced 0.57%
Polypid LTD
-
$0 0.0% of portfolio
-
Q3 2024 Added 66.89%
Structure Therapeutics Inc
-
$0 0.0% of portfolio
-
Q3 2024 Added 580.0%

Summary

  • Portfolio
  • No. of Stocks 84
  • Current Value $389 Million
  • Prior Value $390 Million
  • Filing
  • Period Q3 2024
  • Filing Date November 14, 2024
  • Form Type 13F-HR
  • Activity in Q3 2024
  • New Purchases 6 stocks
  • Additional Purchases 19 stocks
  • Sold out of 0 stocks
  • Reduced holdings in 26 stocks
Track This Portfolio

Track Dafna Capital Management LLC Portfolio

Follow Dafna Capital Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Dafna Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Dafna Capital Management LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email